This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Today's milestone builds on our heritage of developing and delivering novel treatments for patients with advanced renal cell carcinoma, first with the only dual immunotherapy option, Opdivo plus Yervoy, and ... now with a new immunotherapy and tyrosine
The FDA has set a prescription drug user fee act (PDUFA) goal date for a decision on BMS’ immunotherapy regimen of 25 May.
with early-stage, resectable non-small cell lung cancer,” said Patrick Forde, associate professor, Sidney Kimmel Comprehensive Cancer Center and Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University.
The CAR T cell therapy will be manufactured for each individual patient at BMS’ cellular immunotherapy manufacturing facility in Summit, New Jersey. .
Merck &Co’s immunotherapy treatment is the first checkpoint inhibitor to show superior overall survival, progression-free survival and objective response rates for this patient population – regardless of PD-L1 expression
With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning," said Levi Garraway, chief medical ... Keytruda has become a new standard-of
More from news
Approximately 99 fully matching, plus 531 partially matching documents found.
The global pharmaceutical and biotechnology industries have achieved many significant milestones in innovative research and drug development in the past decade – including the broad adoption of immunotherapies and the introduction of
For example, over the last five years, Lundbeck acquired Prexton Therapeutics, Agilent acquired Genohm and Boehringer Ingelheim acquired Amal Therapeutics, focused on cancer immunotherapy and therapeutic cancer vaccines.
Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).
Indeed, 2019 was notable for Bristol-Myers Squibb’s acquisition of Celgene (which at a stroke bolstered its immunotherapy and oncology departments), as well as AbbVie’s acquisition of Allergan for ... Indeed, a key theme of the deals I have mentioned
However, we’re now moving into areas like immunotherapy and are on the edge of amazing innovations that will deliver great outcomes for patients.
More from intelligence
Approximately 5 fully matching, plus 57 partially matching documents found.
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations, Keytruda has become a blockbuster immunotherapy as well as introducing a new standard-of-care for
He joins Galecto from eTheRNA immunotherapies, a Belgian mRNA immunotherapy company.
In his role as CCO at Provention, Hoitt will be responsible for the development and execution of the company’s global commercial strategy for its type 1 diabetes prevention immunotherapy
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
More from appointments
Approximately 2 fully matching, plus 47 partially matching documents found.
Management. Patients with cancer, particularly those receiving chemotherapy, radiotherapy and/or immunotherapy, are at an increased risk of the symptoms and long-term effects of COVID-19 compared with their healthy
If you see the major immunotherapy trials published, there are few Hispanics or Blacks included in the US trials, despite the fact that together they are close to 30% of the
CAR-T is a new individualised cancer immunotherapy that has taken precision medicine to a new level.
SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. ... Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. ... OncoSec's lead immunotherapy platform – TAVO (tavokinogene
More from PMHub
Approximately 11 fully matching, plus 17 partially matching documents found.
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....